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The Special Issue on high grade serous ovarian cancer (HGSOC) and the contribution of the tumor
micro-environment (TME) consisted of reviews contributed by leaders in the ovarian cancer (OC)
field. As HGSOC metastases have a highly complex TME, there is an urgent need to better understand
the TME in general, its distinct components in particular, and the role of the TME in the context of
disease recurrence and development of chemoresistance. The Special Issue integrated the current
understanding of the TME components, including malignant cells, surrounding host stromal cells,
and infiltrating (recruited) immune cells. In addition to cellular contributors to the TME, the role of
ascites fluid components including soluble factors such as cytokines, chemokines, and growth factors;
cell–cell and cell–matrix adhesion molecules; extracellular matrix remodeling; and abnormal vascular
and lymphatic networks were the subject of reviews. Reviews covered the relationship between the
molecular mechanisms of HGSOC progression, including genomic, epigenomic, and transcriptomic
changes, and alterations of the immune cell landscape, as these may provide attractive new molecular
targets for HGSOC therapy.
Prof. Dr. Stack et al. [1] illustrated how the aging process has been shown to modulate the TME
in ways that are beneficial to the spread and survival of ovarian cancer. Aging hosts have been shown
to better facilitate cancer associated inflammation, invasion, and adhesion of cancer cells, while also
putting forth a weakened immune response. More research into the unique features of an aging
peritoneum is needed to better treat aging HGSOC patients.
Prof. Dr. Nephew and Prof. Dr. Klemenko illustrated how cells constituting the TME are also
involved in epigenetic crosstalk with ovarian cancer cells [2]. Ovarian cancer cells have been shown to
epigenetically reprogram a wide variety of cell types in their microenvironment to promote tumor
growth, survival, and metastasis. There is also growing evidence to suggest that cells from the tumor
microenvironment are capable of epigenetically modifying cancer cells. Prof. Dr. Mitra et al. discussed
cancer associated fibroblasts; fibroblasts that have been reprogrammed by cancer cells to support tumor
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growth, survival, and spread, through the secretion of cancer promoting factors. Further research into
their origin and identifying markers is needed in order to better characterize their function within
the TME [3].
There is still a great deal of research to be done regarding the roles of individual proteins in ovarian
cancer. As illustrated by Prof. Dr. Burdette et al. [4], the paired box protein PAX8 is overexpressed in
HGSOCs and confers advantages in growth, survival, and migration. While PAX2 has been shown
to impart similar growth advantages, expression of it is lost early on in carcinogenesis. Prof. Dr.
Hilliard’s review focused on mesothelin which is believed to play a role in survival, proliferation,
tumor progression, and adherence. Though its native biological function is poorly understood, it is
known to bind to the ovarian cancer biomarker CA125, through which it plays a role in metastasis [5].
Prof. Dr. Hudson and colleagues discussed how many of the signaling pathways implicated in HGSOC
converge on the small GTPase Rac1, which is associated not only with actin remodeling, adhesion, and
migration, but also EMT, stemness, angiogenesis, and chemoresistance [6]. Rac1’s role in such a high
number of cancer associated signaling pathways makes it an appealing target for anticancer therapies.
HGSOC presents unique challenges in the development of effective immunotherapies to combat
spread and progression. Prof. Dr. Vanderhyden et al. [7,8] showed how the low mutational burden,
recruitment of T-regs, upregulation of immune checkpoint proteins, and heterogeneity associated with
epithelial ovarian cancer have served as road blocks in the development of ovarian cancer immune
therapies. Prof. Dr. Drakes and Prof. Dr. Stiff illustrated the importance of understanding the factors
in the TME that contribute to the immunogenicity of HGSOC in the development of immune therapies
and more accurate prognosis of patients [9]. Improvements in immune therapies that result from
better characterizing immune modulating TME factors, combined with treatments targeting other
areas of the malignancy are important efforts to increase the survival of patients. In their chapter,
Prof. Dr. Khabele et al. [10,11] illustrated how macrophages in the TME represent cancer promoting
and antitumor forces in ovarian cancer. Cancer promoting M2 tumor associated macrophages (TAM)
represent an attractive target for anticancer therapies. Reprogramming of these M2 cells to M1
tumoricidal macrophages constitutes a promising means of manipulating the TME to be less amenable
to the malignancy.
HGSOC is a malignancy once thought to originate exclusively from the ovarian surface epithelium.
Prof. Dr. Kim et al. [12] reviewed current evidence that suggests HGSOC likely also originates from
serous tubal intraepithelial carcinomas (STICs) from the fallopian tube epithelium. Though STIC has
been shown to correlate with an increased risk of HGSOC, it is still important to show causation.
Additionally, it is important to elucidate the differences between STIC lesions likely to remain benign
vs those that are likely to develop into HGSOC.
Epithelial ovarian cancer is commonly associated with metastasis to the peritoneum, though
it has been shown to colonize a wide range of other tissues. Prof. Dr. Barbolina’s review focused
on the mechanisms of transcoelomic, hematogenous, and lymphatic metastasis [13]. Though most
patients typically succumb to transcoelomic, the presence of distant metastasis is associated with worse
prognosis. As treatment of transcoelomic metastasis improves, it is likely that more research will have
to be devoted to hematogenous and lymphatic spread in order to further improve patient outcomes.
Understanding the interactions between ovarian cancer and metabolites is critical to understanding
and treating the disease. In his review, Prof. Dr. Xu outlined how supportive cells have been shown to
produce cancer-promoting oncolipids [14]. Improvements to existing detection methods will be valuable
in the use of oncolipids as a diagnostic marker in gynecological cancers. Additionally, HGSOC exhibits
a reliance on oxidative phosphorylation for its energy needs, making inhibition of the OXPHOS
pathway an intriguing target for novel therapies. Prof. Dr. Patankar et al. [15] discussed how OXPHOS
inhibition slows proliferation through energy depletion and increases oxidative damage, and through
it, cell death. Development of targeted delivery systems for inhibitors of this pathway are needed.
Given the complex roles that the TME plays in supporting tumors, it follows that more
sophisticated in vitro models are needed to recapitulate the conditions in which cancer cells exist. Prof.
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Dr. Kenny et al. [16] described some of the recent developments in 3D modeling of ovarian cancer.
Models approximating in situ carcinoma in the fallopian tube, dissemination into the peritoneal cavity,
early metastatic attachment to the mesothelial-lined surfaces of the omentum, bowel, and abdominal
wall, and late chemoresistant metastases are needed.
The TME of ovarian cancer has numerous unique features that need to be considered in the study
and treatment of the disease. According to Prof. Dr. O’Hagan and colleagues [17], recent studies
have shown an association between inflammation and an increase in ovarian cancer risk. Though this
phenomenon has been well characterized in colon and pancreatic cancers, the mechanisms through
which inflammation contributes to ovarian cancer risk need further study. Prof. Dr. Hawkins et al. [18]
explained how endometriosis increases the risk of developing endometrioid, clear cell carcinoma, and
low grade serous ovarian cancers. The unique tumor microenvironment created by endometriosis
facilitates tumorigenesis through upregulation of many gene products associated with ovarian cancers.
A number of other therapeutic avenues are being explored in ovarian cancer treatment. Efficient
targeting of a chemoresistant sub-population of cancer cells known as cancer stem cells (CSC) is a
rapidly growing field in the study of high grade serous ovarian cancer. As shown by Prof. Dr. Dahl
and Prof. Dr. Roy, the PI3K/PTEN/AKT, Jak/STAT, NFkB, Notch, Wnt, and Hedgehog pathways have
all been implicated in the maintenance of cancer stem cells, many of which have therapeutics targeting
them currently undergoing clinical trials. Further study is needed to better identify cancer stem cell
populations and the mechanisms through which these pathways are involved in their maintenance.
Another treatment option, known as heated intraperitoneal chemotherapy was discussed by Prof.
Dr. Jewell et al. [19] The higher drug levels delivered through HIPEC combined with hyperthermia are
thought to increase the efficacy of chemotherapy. Studies showing the benefit of HIPEC along with CRS
have been promising, however, use of HIPEC in recurrent cancers warrants further study. The relative
safety of this treatment also warrants further investigation. Strategies for treatments targeting
supportive components of the TME outlined by Prof. Dr. Matei et al. [20] represent a promising
avenue in improving clinical outcomes in patients. Inhibition of angiogenesis, immune therapies, and
therapies targeting supportive stromal cells are being explored as therapies to improve survival in
HGSOC patients, though more research is needed to increase the efficacy of these approaches.
The planning of this special issue was motivated by the Albert Trust Midwest Ovarian Cancer
Coalition (MWOCC) biannual meeting, held in June 2018. We would like to express our deepest
gratitude to the conference sponsor, The Leo and Anne Albert Charitable Trust, Mr. Gene Pranzo
(Trustee), and Susan Brogan (organizer). We sincerely thank all the attendees and participants who
kindly contributed manuscripts of the highest quality to this issue.
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